Xilio Therapeutics Inc
Change company Symbol lookup
Select an option...
XLO Xilio Therapeutics Inc
ORN Orion Group Holdings Inc
SMHI SEACOR Marine Holdings Inc
ASC Ardmore Shipping Corp
CCBC Chino Commercial Bancorp
INGR Ingredion Inc
PROF Profound Medical Corp
VWAGY Volkswagen AG
MLVF Malvern Bancorp Inc
GBCI Glacier Bancorp Inc

Company profile

Xilio Therapeutics, Inc. is a biotechnology company. The Company is focused on harnessing the immune system to achieve clinical responses for cancer patients. It offers a geographically precise solutions (GPS) platform to engineer molecules, including cytokines and other biologics, that are designed to enhance therapeutic index. Using its GPS platform, the Company is engaged in developing a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. Its product candidates include XTX101, XTX202, XTX301, and XTX401. XTX101 is a clinical-stage, tumor-selective anti-cytotoxic T-lymphocyte-associated protein (CTLA-4), monoclonal antibody (mAb), which is designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies. XTX202 and XTX301 are an engineered form of interleukin 2 (IL-2) that is masked with a protein domain to prevent binding activity until the protein domain is cleaved off by tumor microenvironment (TME)-associated proteases.

Closing Price
Day's Change
-0.01 (-0.42%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Scott+Scott Attorneys at Law LLP Announces Securities Investigation into Statements Made by Elon Musk Concerning Announced Acquisition of Twitter, Inc. (TWTR)

10:51 am ET May 17, 2022 (Globe Newswire) Print

EQNX::TICKER_START (NYSE:TWTR), EQNX::TICKER_END Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international shareholder and consumer rights litigation firm, is investigating whether Elon Musk ("Musk") and other individuals with relevant knowledge, violated federal securities laws in connection with statements made concerning Musk's announced acquisition of Twitter, Inc. ("Twitter" or the "Company") (NYSE: TWTR). If you purchased or otherwise acquired Twitter securities and have since suffered a loss, realized or unrealized, you are encouraged to contact Scott+Scott attorney Jonathan Zimmerman at (888) 398-9312 for more information.

On April 25, 2022, Twitter and its board of directors agreed to sell Twitter to Elon Musk for $44 billion.

On May 13, 2022, Elon Musk revealed that he has put the deal to acquire Twitter "on hold" attributing the move to uncertainty around the number of bots, spam and/or fake accounts on the platform, citing to a Reuters story from May 2, 2022 that referenced Twitter's 10-Q filing in which the Company brought up the issue of fake accounts and their responsibility for fewer than 5% of Twitter's monetizable daily active users. On this news, Twitter's stock plunged nearly 10% to close at $40.72 per share.

On May 16, 2022, Bloomberg reported that, while speaking at a private event, Musk suggested that if the deal were to proceed it would have to come at a lower price. On this news, Twitter's stock declined another 8.1%, to close at $37.39 per share.

Then, on May 17, 2022, Musk tweeted that the "deal cannot move forward" until Twitter's CEO shows proof that fake/spam accounts represent less than 5% of Twitters daily active users.

What You Can Do

If you purchased or otherwise own Twitter securities, and you wish to discuss this investigation, please contact attorney Jonathan Zimmerman at (888) 398-9312 or at jzimmerman@scott-scott.com.

About Scott+Scott Attorneys at Law LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.

Attorney Advertising


Jonathan Zimmerman

Scott+Scott Attorneys at Law LLP

230 Park Ave, 17 Fl, NY, NY 10169

(888) 398-9312




comtex tracking


Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.